JP2010516702A5 - - Google Patents

Download PDF

Info

Publication number
JP2010516702A5
JP2010516702A5 JP2009546563A JP2009546563A JP2010516702A5 JP 2010516702 A5 JP2010516702 A5 JP 2010516702A5 JP 2009546563 A JP2009546563 A JP 2009546563A JP 2009546563 A JP2009546563 A JP 2009546563A JP 2010516702 A5 JP2010516702 A5 JP 2010516702A5
Authority
JP
Japan
Prior art keywords
compound according
group
item
prevention
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2009546563A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010516702A (ja
Filing date
Publication date
Priority claimed from PCT/IB2007/002542 external-priority patent/WO2007138485A2/en
Application filed filed Critical
Priority claimed from PCT/US2008/051525 external-priority patent/WO2008089464A1/en
Publication of JP2010516702A publication Critical patent/JP2010516702A/ja
Publication of JP2010516702A5 publication Critical patent/JP2010516702A5/ja
Withdrawn legal-status Critical Current

Links

JP2009546563A 2007-01-18 2008-01-18 置換１，３−ジオキサンのプロドラッグおよびそれらの使用 Withdrawn JP2010516702A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/IB2007/002542 WO2007138485A2 (en) 2006-01-18 2007-01-18 Ppar modulators
US98980507P 2007-11-21 2007-11-21
US98980807P 2007-11-21 2007-11-21
US98980607P 2007-11-21 2007-11-21
PCT/US2008/051525 WO2008089464A1 (en) 2007-01-18 2008-01-18 Prodrugs of substituted 1,3-dioxanes and their uses

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014117213A Division JP2014159487A (ja) 2007-01-18 2014-06-06 置換１，３−ジオキサンのプロドラッグおよびそれらの使用

Publications (2)

Publication Number Publication Date
JP2010516702A JP2010516702A (ja) 2010-05-20
JP2010516702A5 true JP2010516702A5 (enExample) 2011-03-10

Family

ID=41161310

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2009546561A Pending JP2010516700A (ja) 2007-01-18 2008-01-18 置換１，３−ジオキサンおよびそれらの使用
JP2009546560A Expired - Fee Related JP5662682B2 (ja) 2007-01-18 2008-01-18 Ｐｐａｒモジュレータとして有用な置換１，３−ジオキサン
JP2009546563A Withdrawn JP2010516702A (ja) 2007-01-18 2008-01-18 置換１，３−ジオキサンのプロドラッグおよびそれらの使用
JP2009546562A Pending JP2010516701A (ja) 2007-01-18 2008-01-18 置換１，３−ジオキサンおよびそれらの使用
JP2014117213A Pending JP2014159487A (ja) 2007-01-18 2014-06-06 置換１，３−ジオキサンのプロドラッグおよびそれらの使用
JP2014162128A Withdrawn JP2014240409A (ja) 2007-01-18 2014-08-08 Ｐｐａｒモジュレータとして有用な置換１，３−ジオキサン

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2009546561A Pending JP2010516700A (ja) 2007-01-18 2008-01-18 置換１，３−ジオキサンおよびそれらの使用
JP2009546560A Expired - Fee Related JP5662682B2 (ja) 2007-01-18 2008-01-18 Ｐｐａｒモジュレータとして有用な置換１，３−ジオキサン

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2009546562A Pending JP2010516701A (ja) 2007-01-18 2008-01-18 置換１，３−ジオキサンおよびそれらの使用
JP2014117213A Pending JP2014159487A (ja) 2007-01-18 2014-06-06 置換１，３−ジオキサンのプロドラッグおよびそれらの使用
JP2014162128A Withdrawn JP2014240409A (ja) 2007-01-18 2014-08-08 Ｐｐａｒモジュレータとして有用な置換１，３−ジオキサン

Country Status (8)

Country Link
US (5) US20120142766A1 (enExample)
EP (1) EP2120567A4 (enExample)
JP (6) JP2010516700A (enExample)
CN (1) CN101641009A (enExample)
CA (4) CA2676439A1 (enExample)
ES (1) ES2609825T3 (enExample)
MX (4) MX2009007667A (enExample)
WO (1) WO2008089464A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008089461A1 (en) 2007-01-18 2008-07-24 Evolva Sa Substituted 1,3-dioxanes useful as ppar modulators
US20120142766A1 (en) 2007-11-21 2012-06-07 Evolva Sa Substituted 1,3-dioxanes and their uses
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
DE102010015123A1 (de) 2010-04-16 2011-10-20 Sanofi-Aventis Deutschland Gmbh Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013068486A1 (en) 2011-11-08 2013-05-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of male infertility
WO2019079339A1 (en) * 2017-10-18 2019-04-25 Avalon Flaviviral Therapeutics (Hk) Limited COMPOSITIONS AND METHODS FOR BROAD SPECTRUM ANTIVIRAL THERAPY
PL4000615T3 (pl) * 2020-11-13 2022-12-19 Serodus Asa Podwójne antagonisty tnfr1 i agonisty tnfr2 do stosowania w chorobach nerek

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8310407D0 (en) * 1982-05-12 1983-05-25 Ici Plc 1 3 - dioxan -5- ylalkenoic acids
GB8330120D0 (en) * 1983-11-11 1983-12-21 Ici Plc Chemical process
GB8417314D0 (en) * 1984-07-06 1984-08-08 Ici Plc Carboxylic acid derivatives
JPS61215584A (ja) * 1985-03-20 1986-09-25 株式会社日立製作所 表示制御装置
GB8511892D0 (en) * 1985-05-10 1985-06-19 Ici Plc Fluoralkane derivatives
GR861209B (en) 1985-05-10 1986-08-29 Ici Plc Process for preparing novel alkene derivatives
GB8511891D0 (en) * 1985-05-10 1985-06-19 Ici Plc Alkenoic acids
GB8511896D0 (en) * 1985-05-10 1985-06-19 Ici Plc Alkenes
GB8511890D0 (en) * 1985-05-10 1985-06-19 Ici Plc Benzene derivatives
GB8626297D0 (en) * 1986-11-04 1986-12-03 Ici Plc Pharmaceutical compositions
GB8709794D0 (en) * 1987-04-24 1987-05-28 Ici Plc Heterocyclic acids
GB8901201D0 (en) * 1988-02-16 1989-03-15 Ici Plc Pyridine derivatives
US5248780A (en) * 1988-02-16 1993-09-28 Imperial Chemical Industries, Plc Pyridyl substituted alkenoic acid derivatives
GB8808599D0 (en) 1988-04-12 1988-05-11 Glaxo Group Ltd Medicaments
IE81170B1 (en) 1988-10-21 2000-05-31 Zeneca Ltd Pyridine derivatives
US5128359A (en) 1990-02-16 1992-07-07 Laboratoires Upsa Benzimidazole and azabenzimidazole derivatives which are thromboxane receptor antagonists, their methods of preparation
ZA911453B (en) * 1990-03-19 1991-11-27 Squibb & Sons Inc Method of protecting against and/or treating ulcerative gastrointestinal conditions using a thromoboxane,a2 receptor antagonist and combination useful in preventing and/or treating ulcers and/or inflammation
DE4225488A1 (de) 1992-07-30 1994-02-03 Schering Ag Neue Bicyclo[3.3.0]octan-Derivate, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
GB9313649D0 (en) 1993-07-01 1993-08-18 Glaxo Group Ltd Medicaments
US5462726A (en) * 1993-12-17 1995-10-31 Bristol-Myers Squibb Company Method of inhibiting side effects of solvents containing ricinoleic acid or castor oil or derivatives thereof employing a thromboxane A2 receptor antagonist and pharmaceutical compositions containing such solvents
US5801195A (en) * 1994-12-30 1998-09-01 Celgene Corporation Immunotherapeutic aryl amides
AU6263996A (en) 1995-06-07 1996-12-30 Ligand Pharmaceuticals Incorporated Method for screening for receptor agonists and antagonists
US6028052A (en) 1995-09-18 2000-02-22 Ligand Pharmaceuticals Incorporated Treating NIDDM with RXR agonists
GB9600464D0 (en) 1996-01-09 1996-03-13 Smithkline Beecham Plc Novel method
WO1997028149A1 (en) 1996-02-02 1997-08-07 Merck & Co., Inc. Method for raising hdl cholesterol levels
AU6773598A (en) 1997-03-26 1998-10-20 Institut Pasteur Treatment of gastrointestinal disease with ppar modulators
US5981586A (en) * 1997-05-23 1999-11-09 Pershadsingh; Harrihar A. Methods for treating proliferative and inflammatory skin diseases
US6410245B1 (en) 1998-04-01 2002-06-25 Affymax, Inc. Compositions and methods for detecting ligand-dependent nuclear receptor and coactivator interactions
US6436997B1 (en) * 1998-06-01 2002-08-20 Nitromed, Inc. Endogenous nitric oxide synthesis under conditions of low oxygen tension
US6277884B1 (en) * 1998-06-01 2001-08-21 Nitromed, Inc. Treatment of sexual dysfunction with N-hydroxyguanidine compounds
AU761327B2 (en) 1998-08-04 2003-06-05 Toray Industries, Inc. Fused benzene heterocycle derivatives and utilization thereof
US6509348B1 (en) * 1998-11-03 2003-01-21 Bristol-Myers Squibb Company Combination of an ADP-receptor blocking antiplatelet drug and a thromboxane A2 receptor antagonist and a method for inhibiting thrombus formation employing such combination
WO2000030683A1 (en) 1998-11-19 2000-06-02 Shionogi & C0., Ltd. Preventives and/or remedies for central nervous system diseases containing compounds having txa2 receptor antagonism and/or txa2 synthase inhibitory effect
US6291496B1 (en) * 1999-12-27 2001-09-18 Andrew J. Dannenberg Treating cancers associated with overexpression of class I family of receptor tyrosine kinases
WO2001089519A1 (en) 2000-05-22 2001-11-29 Nitromed, Inc. Thromboxane inhibitors, compositions and methods of use related applications
US6284790B1 (en) * 2000-06-15 2001-09-04 Sachin Gupte Methods of potentiating organic nitrates having vasodilating activity and formulations for the same
AU4755502A (en) 2001-06-14 2002-12-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Cofactor-based screening method for nuclear receptor modulators and related modulators
US6951882B2 (en) * 2002-12-12 2005-10-04 Janssen Pharmaceutica N.V. Substituted 4-phenyl-[1,3]-dioxanes
AU2003300867A1 (en) 2002-12-19 2004-07-29 Synaptic Pharmaceutical Corporation Uses of the snorf207 receptor
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
GB0314130D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
WO2005040128A1 (en) 2003-10-24 2005-05-06 Glaxo Group Limited Heterocyclyl compounds
AP2006003688A0 (en) * 2004-01-09 2006-08-31 Cadila Healthcare Ltd 1,3-dioxane derivatives and analogues thereof useful in the treatment of I.A obesity and diabetes
HRP20161602T1 (hr) * 2004-03-29 2016-12-30 Les Laboratoires Servier Postupak priprave čvrstog farmaceutskog pripravka
JP2007536373A (ja) * 2004-05-05 2007-12-13 ファイザー・プロダクツ・インク アトルバスタチンの塩形態
US20070037797A1 (en) 2005-08-15 2007-02-15 Hellstrom Harold R Method of reducing the risk of adverse cardiovascular (CV) events associated with the administration of pharmaceutical agents which favor CV events
WO2007138485A2 (en) * 2006-01-18 2007-12-06 Evolva Sa Ppar modulators
WO2008089461A1 (en) 2007-01-18 2008-07-24 Evolva Sa Substituted 1,3-dioxanes useful as ppar modulators
US20120142766A1 (en) 2007-11-21 2012-06-07 Evolva Sa Substituted 1,3-dioxanes and their uses
WO2009089098A1 (en) 2008-01-03 2009-07-16 Musc Foundation For Research Development Methods for the treatment of cancers

Similar Documents

Publication Publication Date Title
JP2010516702A5 (enExample)
JP2010516700A5 (enExample)
JP2010516701A5 (enExample)
JP2010516699A5 (enExample)
JP5898770B2 (ja) 心血管疾患の治療方法
JP2014511892A5 (enExample)
JP2010529203A5 (enExample)
JP2012525393A5 (enExample)
RU2012121577A (ru) Замещенные 3-фенилпропионовые кислоты и их применение
JP2014525427A5 (enExample)
JP2007502264A5 (enExample)
JP2014511891A5 (enExample)
AU2005224014B9 (en) Use of organic compounds
JP2014525426A5 (enExample)
JP2011521907A5 (enExample)
JP2014525425A5 (enExample)
JP5860895B2 (ja) ５−メチル−１−（ナフタレン−２−イル）−１ｈ−ピラゾール誘導体
JP2017522348A5 (enExample)
JP2018537513A5 (enExample)
JP2006509842A (ja) インドリジン化合物
JP2013544811A5 (enExample)
JP2021529186A (ja) Ｎｌｒｐ調節剤
JP2012107073A (ja) 眼の疾患、ならびに増殖および脈管形成応答に関連する疾患の処置に関する５，６，７−トリヒドロキシヘプタン酸およびアナログ
JP2022173401A (ja) 結晶
JP6959246B2 (ja) 治療に有効な量のジカルボン酸化合物を使用した、病気の予防、治療及び治癒